Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease (Q24200420)

PubMed

21 October 2023

2

Ivan Solà

Ivan

Solà

1 reference

PubMed

22972089

21 October 2023

author name string

Pedro I Martí-Carvajal

series ordinal

3

author given names

Pedro I

author last names

Martí-Carvajal

1 reference

PubMed

22972089

Cochrane Database of Systematic Reviews

21 October 2023

language of work or name

1 reference

12 September 2012

0 references

published in

0 references

cites work

Coagulation disorders in liver disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

How to formulate research recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Molecular mechanisms of fibrinolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Well informed uncertainties about the effects of treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Transfusion-sparing hemostatic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 8. Rating the quality of evidence--indirectness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 9. Rating up the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

General haemostatic agents--fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Better reporting of harms in randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Meta-research: The art of getting it wrong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Fibrinolytic factors in liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Coagulation in hepatobiliary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Coagulopathy in liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Haemostasis and thrombosis in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

The coagulopathy of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Epidemiology of acute upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

7 January 2021

Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

7 January 2021

Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

7 January 2021

Liver cirrhosis, ascites, and hyperfibrinolysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

7 January 2021

Absence of evidence is not evidence of absence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006007.PUB3

7 January 2021

10.1002/14651858.CD006007.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_rmovpkdm65difeatajeq2geide

0 references